Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/comparison-of-immediate-versus-deferred-intravitreal-bevacizumab-in-8p1Xhk5mlp
References (27)
-
M. Ho, D. Liu, D. Lam, J. Jonas (2016)
RETINAL VEIN OCCLUSIONS, FROM BASICS TO THE LATEST TREATMENTRetina, 36
-
M. Laouri, E. Chen, M. Looman, M. Gallagher (2011)
The burden of disease of retinal vein occlusion: review of the literatureEye, 25
-
T. Ach, A. Hoeh, K. Schaal, A. Scheuerle, S. Dithmar (2010)
Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusionGraefe's Archive for Clinical and Experimental Ophthalmology, 248
-
Sachin Jain (2010)
RETINAL DISORDERS -
A. Pielen, N. Feltgen, Christin Isserstedt, J. Callizo, B. Junker, C. Schmucker (2013)
Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic ReviewPLoS ONE, 8
-
S. Rogers, R. Mcintosh, L. Lim, P. Mitchell, N. Cheung, J. Kowalski, Hiep Nguyen, Jie-Jin Wang, T. Wong (2010)
Natural history of branch retinal vein occlusion: an evidence-based systematic review.Ophthalmology, 117 6
-
S. Jeon, Wk Lee (2012)
Aggravated capillary non-perfusion after intravitreal bevacizumab for macular edema secondary to systemic lupus erythematosus and anti-phospholipid syndromeLupus, 21
-
Julie Glanville, J. Patterson, R. McCool, Alberto Ferreira, K. Gairy, I. Pearce (2014)
Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic reviewBMC Ophthalmology, 14
-
P. Campochiaro, David Brown, C. Awh, S. Lee, Sarah Gray, Namrata Saroj, W. Murahashi, Roman Rubio (2011)
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.Ophthalmology, 118 10
-
Masanori Setta, S. Ozaki, A. Tabuchi (2016)
[Long-term Outcomes in Eyes Receiving of Bevacizumab Early in the Course of Branch Retinal Vein Occlusion].Nippon Ganka Gakkai zasshi, 120 5
-
D. Mitry, C. Bunce, D. Charteris (2013)
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.The Cochrane database of systematic reviews, 1
-
Marlene Wang, Karen Jeng-Miller, Henry Feng, J. Prenner, H. Fine, Sumit Shah (2015)
Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselvesBritish Journal of Ophthalmology, 100
-
F. Pichi, C. Specchia, L. Vitale, Andrea Lembo, M. Morara, C. Veronese, A. Ciardella, P. Nucci (2014)
Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion.American journal of ophthalmology, 157 3
-
A. Jaulim, B. Ahmed, T. Khanam, I. Chatziralli (2013)
BRANCH RETINAL VEIN OCCLUSION: Epidemiology, Pathogenesis, Risk Factors, Clinical Features, Diagnosis, and Complications. An Update of the LiteratureRetina, 33
-
DM Brown, PA Campochiaro, RB Bhisitkul, AC Ho, S Gray, N Saroj, AP Adamis, RG Rubio, WY Murahashi (2011)
Sustained benefits from Ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III studyOphthalmology, 118
-
S. Rogers, R. Mcintosh, N. Cheung, L. Lim, Jie-Jin Wang, P. Mitchell, J. Kowalski, Hiep Nguyen, T. Wong (2010)
The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia.Ophthalmology, 117 2
-
Matus Rehak, E. Spies, M. Scholz, P. Wiedemann (2013)
Behandlung der Patienten mit einem Venenastverschluss in Abhängigkeit von der VerschlussdauerDer Ophthalmologe, 110
-
Young Kim, E. Kim, Moosang Kim, Seung-Young Yu, H. Kwak (2009)
Early and Late Intravitreal Bevacizumab Injection in Macular Edema Due to Branch Retinal Vein OcclusionJournal of The Korean Ophthalmological Society, 50
-
S Rogers, RL McIntosh, N Cheung, L Lim, JJ Wang, P Mitchell, JW Kowalski, H Nguyen, TY Wong (2010)
International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology, 117
-
M. Ip, I. Scott, P. Vanveldhuisen, N. Oden, B. Blodi, M. Fisher, L. Singerman, M. Tolentino, C. Chan, V. Gonzalez (2009)
A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.Archives of ophthalmology, 127 9
-
S. Lee, H. Koh (2009)
Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 25 2
-
Daniel Finkelstein (1986)
Argon laser photocoagulation for macular edema in branch vein occlusion.Ophthalmology, 93 7
-
A. Patz (1984)
Argon laser photocoagulation for macular edema in branch vein occlusion.American journal of ophthalmology, 98 3
-
GB Jaissle, P Szurman, N Feltgen, B Spitzer, A Pielen, M Rehak, G Spital, H Heimann, CH Meyer (2011)
Retinal vein occlusion study group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusionGraef’s Arch Clin Exp Ophthalmol, 249
-
T. Katz, A. Frings, S. Linke, G. Richard, V. Druchkiv, J. Steinberg (2014)
Laser in situ keratomileusis for astigmatism ≤ 0.75 Diopter combined with low myopia: a retrospective data analysisBMC Ophthalmology, 14
-
M Rehak, E Spies, M Scholz, P Wiedemann (2013)
Intravitreal treatment of patients with branch retinal vein occlusion depending on the duration of macular edemaDer Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft., 110
-
M. Leitritz, F. Gelisken, F. Ziemssen, P. Szurman, K. Bartz-Schmidt, G. Jaissle (2012)
Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover designBritish Journal of Ophthalmology, 97
- Publisher
- Springer Journals
- Copyright
- Copyright © 2017 by Springer Science+Business Media Dordrecht
- Subject
- Medicine & Public Health; Ophthalmology
- ISSN
- 0165-5701
- eISSN
- 1573-2630
- DOI
- 10.1007/s10792-017-0538-y
- pmid
- 28432581
- Publisher site
- See Article on Publisher Site
Abstract
Int Ophthalmol (2018) 38:943–949 https://doi.org/10.1007/s10792-017-0538-y ORIGINAL PAPER Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study . . M. A. Khan Varakutti Mallika Dattakiran Joshi Received: 6 October 2016 / Accepted: 17 April 2017 / Published online: 21 April 2017 Springer Science+Business Media Dordrecht 2017 Abstract Results The mean visual gain in the two groups early Purpose To compare visual and anatomical recovery and delayed intervention was 0.38 log MARs and 0.15 of immediate versus deferred intravitreal Beva- log MAR units, respectively, and the superior vision cizumab for the treatment of macular oedema sec- gain in the early intervention group was statistically ondary to branch retinal vein occlusion (BRVO). significant (p \ 0.001). The difference in visual Methods In a pilot study, 40 treatment naı¨ve patients improvement between the two groups persisted till of branch retinal vein occlusion with macular oedema 1 year of follow-up. The early intervention group and vision 6/12 or less presenting within one month of required fewer injections (2.6 ± 71 vs. 3.5 ± 0.51), onset were randomised into 2 groups (20 each) to and rescue laser treatment (15 vs. 25%) as compared to receive
Journal
International Ophthalmology – Springer Journals
Published: Apr 21, 2017